05-05-2025
Biocon share price jumps 4% after its subsidiary receives multiple market access agreements for Yesintek
Biocon shares jumped 4% in early trade after the company announced that its subsidiary, Biologics, had significant U.S. market access agreements for its biosimilar Yesintek™ (ustekinumab-kfce). As of 10:20 AM, the shares were trading 4.81% higher at Rs 334.25.
Approved by the U.S. FDA in December 2024, Yesintek is a biosimilar to Johnson & Johnson's Stelara®, used to treat autoimmune conditions like Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Effective March 21, 2025, Express Scripts added Yesintek to its National Preferred Formulary. Major insurers and pharmacy benefit managers (PBMs) including Cigna, UnitedHealthcare, CVS Health, and Optum Rx have followed suit, with coverage expanding from March to July 2025 across commercial, Medicare, and Medicaid plans.
Regional payers like Navitus, Costco Health Solutions, MedImpact, and UPMC have also adopted the drug. Notably, BCBS of Michigan and Florida Healthcare Plan will list Yesintek as their exclusive ustekinumab option.
Yesintek is available in all dosage forms matching Stelara, including prefilled syringes and vials. As an interleukin-12 and interleukin-23 inhibitor, the monoclonal antibody targets inflammation in autoimmune diseases. Clinical data confirms its equivalence in efficacy, safety, and immunogenicity to the reference drug.
Biocon shares opened at ₹322.00 and reached a high of ₹334.40 today, maintaining the day's low at ₹322.00. The stock remains active within its 52-week range, with a high of ₹404.70 and a low of ₹269.55.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
